Status:
COMPLETED
Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients With Newly Diagnosed Type 2 Diabetes
Lead Sponsor:
Beijing Chao Yang Hospital
Conditions:
Type2 Diabetes
Eligibility:
All Genders
20-65 years
Phase:
PHASE4
Brief Summary
The present study assessed the therapeutic effect of exenatide and metformin as the initial therapy in overweight/obese patients with newly diagnosed Type 2 diabetes (T2D).
Detailed Description
The present study was a prospective, nonrandomized, interventional study.The drug-naïve, overweight or obese patients with newly diagnosed T2D were consecutively enrolled. The inclusion criteria: 1) a...
Eligibility Criteria
Inclusion
- age 20 - \<65 years,
- body mass index (BMI) ≥ 24 kg/m2,
- HbA1c ≥ 7% (53mmol/mol).
- diabetes antibodies (-)
- diagnosed with T2D within the previous 3 months
Exclusion
- anti-diabetic drugs or diet therapy before participation
- pancreatitis
- coronary artery disease
- liver function impairment
- renal function impairment
- intestinal surgery
- chronic hypoxic diseases (emphysema and cor pulmonale)
- infectious disease
- hematological disease
- systemic inflammatory disease
- cancer
- pregnant, possibly pregnant
- ingesting agents known to influence glucose or lipid metabolism
Key Trial Info
Start Date :
January 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2016
Estimated Enrollment :
230 Patients enrolled
Trial Details
Trial ID
NCT03297879
Start Date
January 1 2013
End Date
February 28 2016
Last Update
October 2 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.